BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
GET POWR RATINGS... FREE!
BTAI Stock Price Chart Interactive Chart >
BTAI Price/Volume Stats
| Current price | $15.61 | 52-week high | $24.57 |
| Prev. close | $15.51 | 52-week low | $8.80 |
| Day low | $15.32 | Volume | 54,000 |
| Day high | $15.77 | Avg. volume | 466,807 |
| 50-day MA | $12.44 | Dividend yield | N/A |
| 200-day MA | $14.35 | Market Cap | 437.42M |
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Latest BTAI News From Around the Web
Below are the latest news stories about BIOXCEL THERAPEUTICS INC that investors may wish to consider to help them evaluate BTAI as an investment opportunity.
Is This Soaring Growth Stock a Buy?BioXcel remains deep in the red for the year, but ongoing developments have helped fuel the company's recent run. It has just one product on the market, Igalmi, a sublingual film that treats acute agitation (intense anxiety often accompanied by excessive or aggressive activity) in patients with schizophrenia and bipolar disorder 1 or 2. In the third quarter, the company reported revenue of just $137,000. |
BioXcel Therapeutics to Present at Two Upcoming Investor ConferencesNEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in fireside chats at two upcoming investor conferences. Management will discuss the Company’s neuroscience and immuno-onco |
BTAI: Positive Early Metrics for IGALMI™ Launch…By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Commercial Day Highlights Positive Early Launch Metrics for IGALMI™ On October 18, 2022, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) hosted a Commercial Day presentation to provide an update on the recent launch of IGALMI™, which is approved for the acute treatment of agitation associated with schizophrenia or bipolar |
BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational HighlightsIGALMI™ (dexmedetomidine) well-positioned for growth in 2023 based on increasing market access, efficient targeting, favorable market drivers, and sales force expansion in all major U.S. geographies Top-line pivotal data for TRANQUILITY II trial investigating BXCL501 for Alzheimer’s-related agitation expected in 1H 2023 Top-line pivotal data for SERENITY III trial investigating at-home use of BXCL501 for acute treatment of bipolar and schizophrenia-related agitation expected in 1H 2023 Completed |
Mizuho Securities Sticks to Their Buy Rating for Bioxcel Therapeutics (BTAI)E ratio of -2.81. |
BTAI Price Returns
| 1-mo | 30.74% |
| 3-mo | 13.61% |
| 6-mo | N/A |
| 1-year | -30.87% |
| 3-year | 145.83% |
| 5-year | N/A |
| YTD | -23.22% |
| 2021 | -56.00% |
| 2020 | 216.22% |
| 2019 | 278.50% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...